Needham Reiterates Buy on Conmed, Maintains $139 Price Target
Portfolio Pulse from richadhand@benzinga.com
Needham analyst Mike Matson has reiterated a 'Buy' rating on Conmed (NYSE:CNMD) and maintained a price target of $139.
July 24, 2023 | 11:03 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Mike Matson has reiterated a 'Buy' rating on Conmed and maintained a price target of $139.
The reiteration of a 'Buy' rating by a Needham analyst indicates a positive outlook for Conmed. The maintained price target of $139 suggests that the analyst believes the stock is still undervalued, which could lead to upward pressure on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100